Cayman
Showing 37951–38100 of 45550 results
-
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 25 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 250 mgAvailable on backorder
Rimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.{22179} It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).{43207,43208} Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).{42218} It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.{43209} It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).{43210} Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
Brand:CaymanSKU:23838 - 50 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 1 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 10 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 25 mgAvailable on backorder
Rimegepant is an orally bioavailable antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM).{47524} It inhibits cAMP production stimulated by α-CGRP (Item No. 24405) in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Rimegepant (7 mg/kg, s.c.) reduces human α-CGRP-induced increases in facial blood flow, a surrogate for changes in intracranial artery diameter, in anesthetized marmosets.
Brand:CaymanSKU:26338 - 5 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 10 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 25 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 5 mgAvailable on backorder
Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Kis = 5.6 and >1,000 nM for CB1 and CB2, respectively).{3133} In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.{17168} Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.{17167}
Brand:CaymanSKU:9000484 - 50 mgAvailable on backorder
Rimonabant-d10 contains 10 deuterium atoms at the 2, 2’, 3, 3’, 4, 4’, 5, 5’, 6, and 6’ positions. It is intended for use as an internal standard for the quantification of rimonabant (Item No. 9000484) by GC- or LC-MS. Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant and anti-obesity drug.{3133} It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects.
Brand:CaymanSKU:9001821 - 1 mgAvailable on backorder
Rimonabant-d10 contains 10 deuterium atoms at the 2, 2’, 3, 3’, 4, 4’, 5, 5’, 6, and 6’ positions. It is intended for use as an internal standard for the quantification of rimonabant (Item No. 9000484) by GC- or LC-MS. Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant and anti-obesity drug.{3133} It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects.
Brand:CaymanSKU:9001821 - 500 µgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 10 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 25 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 5 mgAvailable on backorder
Riociguat is a stimulator of soluble guanylate cyclase (sGC).{36864},{26751} It stimulates recombinant sGC in a concentration-dependent manner in vitro by up to 73-fold when used at a concentration of 100 μM or by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate (Item No. 82100).{36864} It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 (Item No. 16450). It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.
Brand:CaymanSKU:9000554 - 50 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 1 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 10 mgAvailable on backorder
RIPGBM is a prodrug form of the pro-apoptotic compound cRIPGBM.{35798} It is converted to cRIPGBM in GBM-1 glioblastoma multiforme (GBM) cancer stem cells (CSCs) but not primary human lung fibroblasts (HLFs). RIPGBM induces apoptosis in GBM CSCs (EC50 = ≤500 nM) and selectively reduces survival of GBM-1 cells (EC50 = 0.22 μM) over human neural stem cells, primary human astrocytes, and primary HLFs (EC50s = 1.7, 2.9, and 3.5 μM, respectively). It reduces tumor growth in a GBM mouse xenograft model using patient-derived GBM-39 cells engineered to express IR fluorescent protein 720 (IRFP720) when administered at a dose of 50 mg/kg twice per day.
Brand:CaymanSKU:27860 - 5 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 1 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 10 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 25 mgAvailable on backorder
Risdiplam is a survival of motor neuron-2 (SMN2) splicing modifier.{50413} It enhances SMN2 splicing (EC1.5x = 40 nM) and increases SMN protein levels (EC1.5x = 163 nM) in cellular assays. Risdiplam (3 mg/kg) increases brain and quadricep muscle SMN protein levels in the adult C/C-allele mouse model of mild spinal muscular atrophy (SMA) and the SMND7 neonate mouse model of severe SMA. It also increases the number of vesicular glutamate transporter 1 (vGLUT1) proprioceptive inputs on motor neurons, the number of L3 to L5 spinal motor neurons, the percentage of fully innervated neuromuscular junctions (NMJs), and the size of the extensor digitorum longus muscles in adult SMND7 mice. Formulations containing risdiplam have been used in the treatment of spinal muscular atrophy.
Brand:CaymanSKU:29028 - 5 mgAvailable on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risedronate is a heterocyclic orally active aminobisphosphonate.{32680} Like other bisphosphonates, it inhibits bone resorption.{32679,32680} In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).{35110} It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.{21586,32679,32680}
Brand:CaymanSKU:20740 -Available on backorder
Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:- Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:- Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:-
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.{34751,34752} Risperidone (Item No. 13629) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.{17629,17608} This second-generation antipsychotic was designed to antagonize both D2 and 5-HT2A receptors.{22210,21347} It has little effect on cholinergic and β-adrenergic receptors but does affect α2-adrenergic and histamine H1 receptors.{22210,21347}
Brand:CaymanSKU:22156 -Out of stock
Risperidone-d5 is intended for use as an internal standard for the quantification of risperidone (Item No. 13629) by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:10010570 - 1 mgAvailable on backorder
Risperidone-d5 is intended for use as an internal standard for the quantification of risperidone (Item No. 13629) by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.
Brand:CaymanSKU:10010570 - 500 µgAvailable on backorder
Ristocetin A is an antibiotic that was used to treat staphylococcal infections.{32140} However, side effects of ristocetin A included thrombocytopenia and platelet agglutination. Ristocetin A is now used in two assays related to these actions, the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. Both assays are used in the diagnosis of von Willebrand disease and other bleeding disorders.{32139,32140}
Brand:CaymanSKU:20601 -Available on backorder
Ristocetin A is an antibiotic that was used to treat staphylococcal infections.{32140} However, side effects of ristocetin A included thrombocytopenia and platelet agglutination. Ristocetin A is now used in two assays related to these actions, the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. Both assays are used in the diagnosis of von Willebrand disease and other bleeding disorders.{32139,32140}
Brand:CaymanSKU:20601 -Available on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 1 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 10 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 5 mgAvailable on backorder
HDM-2 (human double minute-2; MDM-2 in mouse) is a key negative regulator of p53 that binds to and targets p53 for proteasomal degradation. Overexpression of HDM-2 in some tumors leads to inactivation of p53 thereby allowing tumor cells to escape p53-induced apoptosis.{13684} RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53.{12386} It binds to p53 with an apparent Kd of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation and activation.{12386} RITA potently inhibits the growth of a variety of cancer cell lines in the sub-micromolar range, inducing both DNA-protein and DNA-DNA cross links in human renal cancer cells.{13683} RITA reduced tumor size by 90% at a dose of 10 mg/kg in SCID mice bearing HCT116 tumors, and caused complete regression of A-498 tumor cell xenografts in nude mice at a dose of 45 mg/kg.{12386,13682}
Brand:CaymanSKU:10006426 - 50 mgAvailable on backorder
Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:- Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:- Ritalinic acid is an inactive, major metabolite of methylphenidate (Item No. 11639), a schedule II drug in the United States commonly used as a psychostimulant for the treatment of attention-deficit hyperactivity disorder, also known as ADHD.{22009} Ritalinic acid is reported to reach plasma concentrations of 1-2 orders of magnitude greater than that of the parent drug and has been monitored in urine to ensure compliance with treatment programs.{25908} This product is intended for forensic and biological research purposes.
Brand:CaymanSKU:-
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock
Ritanserin is a selective antagonist of the serotonin (5-HT) receptor subtype, 5-HT2A.{39295} In a radioligand binding assay, ritanserin exhibits high selectivity for 5-HT2A over 5-HT1 receptors (IC50s = 0.9 nM and >1000 nM, respectively).{39296} It also demonstrates relatively low affinity for histamine H1, dopamine D2, α1-adrenergic, and α2-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT2A, respectively). Ritanserin (2.5 mg/kg) is long-acting, occupying >70% of 5-HT2A sites up to 48 hours following subcutaneous administration to rats and guinea pigs. In vivo, ritanserin (10 mg/kg) blocks 5-hydroxy tryptophan-induced head twitches in rats.{39297}
Brand:CaymanSKU:21374 -Out of stock
Ritodrine is an agonist of β2-adrenergic receptors (β2-ARs).{47089} It induces relaxation of isolated pig detrusor muscle when used at concentrations ranging from 0.001 to 1 μM. Ritodrine (30 μg/ml) reduces electrically-induced isometric tension in myometrial strips isolated from rabbits on day 25 of pregnancy.{47090} It also suppresses spontaneous motility of and increases concentration of cyclic AMP (cAMP) in isolated pregnant rat uterus.{47091} Formulations containing ritodrine were previously used to stop premature labor.
Brand:CaymanSKU:26084 - 1 gAvailable on backorder
Ritodrine is an agonist of β2-adrenergic receptors (β2-ARs).{47089} It induces relaxation of isolated pig detrusor muscle when used at concentrations ranging from 0.001 to 1 μM. Ritodrine (30 μg/ml) reduces electrically-induced isometric tension in myometrial strips isolated from rabbits on day 25 of pregnancy.{47090} It also suppresses spontaneous motility of and increases concentration of cyclic AMP (cAMP) in isolated pregnant rat uterus.{47091} Formulations containing ritodrine were previously used to stop premature labor.
Brand:CaymanSKU:26084 - 250 mgAvailable on backorder
Ritodrine is an agonist of β2-adrenergic receptors (β2-ARs).{47089} It induces relaxation of isolated pig detrusor muscle when used at concentrations ranging from 0.001 to 1 μM. Ritodrine (30 μg/ml) reduces electrically-induced isometric tension in myometrial strips isolated from rabbits on day 25 of pregnancy.{47090} It also suppresses spontaneous motility of and increases concentration of cyclic AMP (cAMP) in isolated pregnant rat uterus.{47091} Formulations containing ritodrine were previously used to stop premature labor.
Brand:CaymanSKU:26084 - 5 gAvailable on backorder
Ritodrine is an agonist of β2-adrenergic receptors (β2-ARs).{47089} It induces relaxation of isolated pig detrusor muscle when used at concentrations ranging from 0.001 to 1 μM. Ritodrine (30 μg/ml) reduces electrically-induced isometric tension in myometrial strips isolated from rabbits on day 25 of pregnancy.{47090} It also suppresses spontaneous motility of and increases concentration of cyclic AMP (cAMP) in isolated pregnant rat uterus.{47091} Formulations containing ritodrine were previously used to stop premature labor.
Brand:CaymanSKU:26084 - 500 mgAvailable on backorder
Ritonavir is an HIV protease inhibitor.{24746} It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively).{24746,26076} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM).{24198} It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.{42447} Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.
Brand:CaymanSKU:- Ritonavir is an HIV protease inhibitor.{24746} It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively).{24746,26076} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM).{24198} It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.{42447} Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.
Brand:CaymanSKU:- Ritonavir is an HIV protease inhibitor.{24746} It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively).{24746,26076} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM).{24198} It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.{42447} Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.
Brand:CaymanSKU:-
Ritonavir-d6 is intended for use as an internal standard for the quantification of ritonavir (Item No. 13872) by GC- or LC-MS. Ritonavir is an HIV protease inhibitor.{24746} It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively).{24746,26076} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM).{24198} It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.{42447} Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.
Brand:CaymanSKU:25462 - 1 mgAvailable on backorder
Ritonavir-d6 is intended for use as an internal standard for the quantification of ritonavir (Item No. 13872) by GC- or LC-MS. Ritonavir is an HIV protease inhibitor.{24746} It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively).{24746,26076} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM).{24198} It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.{42447} Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.
Brand:CaymanSKU:25462 - 500 µgAvailable on backorder
Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases.{25094} In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:- Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases.{25094} In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:- Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases.{25094} In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:- Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases.{25094} In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:-
Rivaroxaban-d4 is intended for use as an internal standard for the quantification of rivaroxaban (Item No. 16043) by GC- or LC-MS. Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time. Formulations containing rivaroxaban have been used as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:22563 -Out of stock
Rivaroxaban-d4 is intended for use as an internal standard for the quantification of rivaroxaban (Item No. 16043) by GC- or LC-MS. Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.{25094} It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time. Formulations containing rivaroxaban have been used as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.{26130,26131}
Brand:CaymanSKU:22563 -Out of stock
Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871}. In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:- Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871}. In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:- Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871}. In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:- Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871}. In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:-
Rivastigmine-d6 is intended for use as an internal standard for the quantification of rivastigmine (Item No. 14270) by GC- or LC-MS. Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyrl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871} In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:25633 - 1 mgAvailable on backorder
Rivastigmine-d6 is intended for use as an internal standard for the quantification of rivastigmine (Item No. 14270) by GC- or LC-MS. Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyrl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).{24084} It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.{36871} In a rat model of Alzheimer’s disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.{36872} It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer’s disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.{36873} Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Brand:CaymanSKU:25633 - 500 µgAvailable on backorder
Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively).{10581} It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.{10581,18823,18825,18824,18827} Rivenprost has also been used to support wound healing.{18826}
Brand:CaymanSKU:- Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively).{10581} It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.{10581,18823,18825,18824,18827} Rivenprost has also been used to support wound healing.{18826}
Brand:CaymanSKU:- Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively).{10581} It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.{10581,18823,18825,18824,18827} Rivenprost has also been used to support wound healing.{18826}
Brand:CaymanSKU:-
Rizatriptan is an orally bioavailable agonist at the serotonin (5-HT) receptor subtypes, 5-HT1B and 5-HT1D, with Ki values of 10.1 and 4.3 nM, respectively.{34530} It is less selective for the 5-HT1A receptor subtype (Ki = 140 nM). Rizatriptan has vasoconstrictive properties, which are more potent in isolated cranial arteries than coronary arteries.{34529} Formulations containing rizatriptan are used to treat patients with migraine headaches.
Brand:CaymanSKU:-Out of stock
Rizatriptan is an orally bioavailable agonist at the serotonin (5-HT) receptor subtypes, 5-HT1B and 5-HT1D, with Ki values of 10.1 and 4.3 nM, respectively.{34530} It is less selective for the 5-HT1A receptor subtype (Ki = 140 nM). Rizatriptan has vasoconstrictive properties, which are more potent in isolated cranial arteries than coronary arteries.{34529} Formulations containing rizatriptan are used to treat patients with migraine headaches.
Brand:CaymanSKU:-Out of stock
Rizatriptan is an orally bioavailable agonist at the serotonin (5-HT) receptor subtypes, 5-HT1B and 5-HT1D, with Ki values of 10.1 and 4.3 nM, respectively.{34530} It is less selective for the 5-HT1A receptor subtype (Ki = 140 nM). Rizatriptan has vasoconstrictive properties, which are more potent in isolated cranial arteries than coronary arteries.{34529} Formulations containing rizatriptan are used to treat patients with migraine headaches.
Brand:CaymanSKU:-Out of stock
Rizatriptan is an orally bioavailable agonist at the serotonin (5-HT) receptor subtypes, 5-HT1B and 5-HT1D, with Ki values of 10.1 and 4.3 nM, respectively.{34530} It is less selective for the 5-HT1A receptor subtype (Ki = 140 nM). Rizatriptan has vasoconstrictive properties, which are more potent in isolated cranial arteries than coronary arteries.{34529} Formulations containing rizatriptan are used to treat patients with migraine headaches.
Brand:CaymanSKU:-Out of stock
RJR 2429 is a nicotinic acetylcholine receptor (AChR) agonist.{49443} It is selective for α4β2 or α7 subunit-containing nicotinic AChRs (Kis = 0.7 and 10.9 nM in isolated rat cortex and isolated rat hippocampus, respectively) over α1βɣδ subunit-containing nicotinic AChRs (EC50 = 1,000 nM in PC12 cells). RJR 2429 induces dopamine release from isolated rat striatal synaptosomes (EC50 = 2.4 nM) and increases nicotine-induced elevations in epinephrine and norepinephrine levels in isolated rat adrenal gland when used at a concentration of 100 µM.{49444},{49446} It inhibits nicotine-induced ion flux in isolated rat thalamic synaptosomes (IC50 = 154 nM).{49444}
Brand:CaymanSKU:29745 - 10 mgAvailable on backorder
RJR 2429 is a nicotinic acetylcholine receptor (AChR) agonist.{49443} It is selective for α4β2 or α7 subunit-containing nicotinic AChRs (Kis = 0.7 and 10.9 nM in isolated rat cortex and isolated rat hippocampus, respectively) over α1βɣδ subunit-containing nicotinic AChRs (EC50 = 1,000 nM in PC12 cells). RJR 2429 induces dopamine release from isolated rat striatal synaptosomes (EC50 = 2.4 nM) and increases nicotine-induced elevations in epinephrine and norepinephrine levels in isolated rat adrenal gland when used at a concentration of 100 µM.{49444},{49446} It inhibits nicotine-induced ion flux in isolated rat thalamic synaptosomes (IC50 = 154 nM).{49444}
Brand:CaymanSKU:29745 - 25 mgAvailable on backorder
RJR 2429 is a nicotinic acetylcholine receptor (AChR) agonist.{49443} It is selective for α4β2 or α7 subunit-containing nicotinic AChRs (Kis = 0.7 and 10.9 nM in isolated rat cortex and isolated rat hippocampus, respectively) over α1βɣδ subunit-containing nicotinic AChRs (EC50 = 1,000 nM in PC12 cells). RJR 2429 induces dopamine release from isolated rat striatal synaptosomes (EC50 = 2.4 nM) and increases nicotine-induced elevations in epinephrine and norepinephrine levels in isolated rat adrenal gland when used at a concentration of 100 µM.{49444},{49446} It inhibits nicotine-induced ion flux in isolated rat thalamic synaptosomes (IC50 = 154 nM).{49444}
Brand:CaymanSKU:29745 - 5 mgAvailable on backorder
RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 µM, respectively).{24190} It also inhibits BLK, Csk, Fyn, and Lyn (IC50s = 0.37, 4.27, 2.03, and 0.43 µM, respectively). RK-20448 is the cis isomer of A-419259 (Item No. 18168).
Brand:CaymanSKU:25606 - 1 mgAvailable on backorder